Logo image of UROY

URANIUM ROYALTY CORP (UROY) Stock Fundamental Analysis

NASDAQ:UROY - Nasdaq - CA91702V1013 - Common Stock - Currency: USD

2.59  +0.03 (+1.17%)

After market: 2.62 +0.03 (+1.16%)

Fundamental Rating

2

Taking everything into account, UROY scores 2 out of 10 in our fundamental rating. UROY was compared to 209 industry peers in the Oil, Gas & Consumable Fuels industry. UROY scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. UROY is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year UROY has reported negative net income.
UROY had a negative operating cash flow in the past year.
In the past 5 years UROY reported 4 times negative net income.
In the past 5 years UROY always reported negative operating cash flow.
UROY Yearly Net Income VS EBIT VS OCF VS FCFUROY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 -20M -40M -60M -80M -100M

1.2 Ratios

UROY has a Return On Assets of -1.91%. This is in the lower half of the industry: UROY underperforms 70.81% of its industry peers.
UROY has a worse Return On Equity (-1.92%) than 68.42% of its industry peers.
Industry RankSector Rank
ROA -1.91%
ROE -1.92%
ROIC N/A
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
UROY Yearly ROA, ROE, ROICUROY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15

1.3 Margins

With a Gross Margin value of 22.68%, UROY is not doing good in the industry: 65.07% of the companies in the same industry are doing better.
The Profit Margin and Operating Margin are not available for UROY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.68%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UROY Yearly Profit, Operating, Gross MarginsUROY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40

More info and screens

6

2. Health

2.1 Basic Checks

UROY does not have a ROIC to compare to the WACC, probably because it is not profitable.
UROY has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, UROY has more shares outstanding
UROY has a worse debt/assets ratio than last year.
UROY Yearly Shares OutstandingUROY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
UROY Yearly Total Debt VS Total AssetsUROY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 242.89 indicates that UROY is not in any danger for bankruptcy at the moment.
UROY's Altman-Z score of 242.89 is amongst the best of the industry. UROY outperforms 99.52% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that UROY is not too dependend on debt financing.
UROY has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. UROY outperforms 85.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 242.89
ROIC/WACCN/A
WACC8.22%
UROY Yearly LT Debt VS Equity VS FCFUROY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

UROY has a Current Ratio of 233.49. This indicates that UROY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of UROY (233.49) is better than 100.00% of its industry peers.
A Quick Ratio of 20.25 indicates that UROY has no problem at all paying its short term obligations.
The Quick ratio of UROY (20.25) is better than 97.13% of its industry peers.
Industry RankSector Rank
Current Ratio 233.49
Quick Ratio 20.25
UROY Yearly Current Assets VS Current LiabilitesUROY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for UROY have decreased strongly by -154.13% in the last year.
The Revenue for UROY has decreased by -63.48% in the past year. This is quite bad
EPS 1Y (TTM)-154.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)-63.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.31%

3.2 Future

Based on estimates for the next years, UROY will show a very negative growth in Earnings Per Share. The EPS will decrease by -112.21% on average per year.
Based on estimates for the next years, UROY will show a very negative growth in Revenue. The Revenue will decrease by -37.67% on average per year.
EPS Next Y-349.93%
EPS Next 2Y144.89%
EPS Next 3Y-112.21%
EPS Next 5YN/A
Revenue Next Year110.16%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.67%
Revenue Next 5YN/A

3.3 Evolution

UROY Yearly Revenue VS EstimatesUROY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 10M 20M 30M 40M
UROY Yearly EPS VS EstimatesUROY Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 0 0.05 -0.05

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

UROY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UROY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UROY Price Earnings VS Forward Price EarningsUROY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UROY Per share dataUROY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

A cheap valuation may be justified as UROY's earnings are expected to decrease with -112.21% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y144.89%
EPS Next 3Y-112.21%

More info and screens

0

5. Dividend

5.1 Amount

UROY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

URANIUM ROYALTY CORP

NASDAQ:UROY (8/21/2025, 8:00:02 PM)

After market: 2.62 +0.03 (+1.16%)

2.59

+0.03 (+1.17%)

Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryOil, Gas & Consumable Fuels
Earnings (Last)07-16 2025-07-16/amc
Earnings (Next)09-10 2025-09-10
Inst Owners27.67%
Inst Owner Change17.8%
Ins Owners2.18%
Ins Owner ChangeN/A
Market Cap346.13M
Analysts77.5
Price Target3.52 (35.91%)
Short Float %9.44%
Short Ratio3.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)50.5%
Min EPS beat(2)0.99%
Max EPS beat(2)100%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-82.27%
Min Revenue beat(2)-99.97%
Max Revenue beat(2)-64.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.3%
PT rev (3m)1.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)114.7%
Revenue NY rev (3m)114.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.78
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)-0.01
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0.08
BVpS1.59
TBVpS1.59
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.91%
ROE -1.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.68%
FCFM N/A
ROA(3y)-0.51%
ROA(5y)-1.15%
ROE(3y)-0.57%
ROE(5y)-1.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9653.33%
Cap/Sales 74.28%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 233.49
Quick Ratio 20.25
Altman-Z 242.89
F-Score2
WACC8.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-154.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y-349.93%
EPS Next 2Y144.89%
EPS Next 3Y-112.21%
EPS Next 5YN/A
Revenue 1Y (TTM)-63.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-62.31%
Revenue Next Year110.16%
Revenue Next 2Y-75.5%
Revenue Next 3Y-37.67%
Revenue Next 5YN/A
EBIT growth 1Y-167.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.09%
EBIT Next 3Y3.33%
EBIT Next 5YN/A
FCF growth 1Y68.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.37%
OCF growth 3YN/A
OCF growth 5YN/A